Stoke Therapeutics (STOK) reported a Q2 loss late Tuesday of $0.40 per diluted share, narrower than a loss of $0.46 a year earlier.
Analysts polled by FactSet expected a loss of $0.57.
Revenue for the quarter ended June 30 rose to $13.8 million from $4.8 million a year earlier.
Analysts surveyed by FactSet expected $8.9 million.